2. Others
  3. Drug Derivative
  4. Verbascosaponin

Verbascosaponin  (Synonyms: Ilwensisaponin A; Mimengoside A)

Cat. No.: HY-N19870
Handling Instructions Technical Support

Verbascosaponin (Ilwensisaponin A) is an orally active oleanane-triterpene saikosaponin found in crophularia auriculata ssp. pseudoauriculata. Verbascosaponin can be used for the research of inflammation.

For research use only. We do not sell to patients.

Verbascosaponin

Verbascosaponin Chemical Structure

CAS No. : 141896-30-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Verbascosaponin Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Verbascosaponin (Ilwensisaponin A) is an orally active oleanane-triterpene saikosaponin found in crophularia auriculata ssp. pseudoauriculata. Verbascosaponin can be used for the research of inflammation[1].

In Vivo

Verbascosaponin (100 mg/kg; p.o.; single dose; 1 hour prior to inflammation induction) significantly inhibits Carrageenan (HY-125474)-induced mouse paw edema[1].
Verbascosaponin (0.075-0.600 mg/ear; topical; single dose) potently inhibits single-dose TPA (HY-18739)-induced mouse ear edema with an ID50 of 0.18 μmol/ear[1].
Verbascosaponin (0.5 mg/ear; topical; single dose; 30 minutes prior to inflammation induction) does not produce appreciable inhibition of Arachidonic acid (HY-109590)-induced mouse ear edema, with only 4% reduction observed[1].
Verbascosaponin (0.5 mg/ear; topical; single dose; 16 hours prior to inflammation induction) does not significantly inhibit Ethyl phenylpropiolate-induced mouse ear edema, with only 2% reduction observed[1].
Verbascosaponin (0.5 mg/ear; topical; twice daily; 4 days) significantly inhibits TPA-induced chronic mouse ear edema by 58% and reduces neutrophil infiltration by 65%[1].
Verbascosaponin (0.5 mg/ear; topical; doses at 6, 24, 48, 72, and 96 hours post-challenge) moderately inhibits Oxazolone (HY-126360)-induced delayed-type hypersensitivity mouse ear edema, with 32% reduction observed at 24 hours post-challenge, but does not reduce neutrophil infiltration[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Swiss mice (female, 25-30 g)[1]
Dosage: 100 mg/kg
Administration: p.o.; single dose; 1 hour prior to inflammation induction
Result: Inhibited paw edema by >50% at 1 hour.
Showed slightly decreased inhibitory effects over time, with unspecified reduction values at 3 and 5 hours.
Animal Model: Swiss mice (female, 25-30 g)[1]
Dosage: 0.5 mg/ear
Administration: topical; single dose
Result: Achieved 72% edema inhibition of TPA (HY-18739)-induced ear edema.
Animal Model: Swiss mice (female, 25-30 g)[1]
Dosage: 0.5 mg/ear
Administration: topical; single dose
Result: Produced only 4% inhibition of Arachidonic acid-induced ear edema, an insignificant effect.
Animal Model: Swiss mice (female, 25-30 g)[1]
Dosage: 0.5 mg/ear
Administration: topical; single dose; 16 hours prior to inflammation induction; simultaneous with inflammation induction
Result: Reduced edema by only 2% (not significant) when administered 16 hours before ethyl phenylpropiolate.
Showed a slight inflammatory effect with no significant edema inhibition when administered simultaneously.
Animal Model: Swiss mice (female, 25-30 g)[1]
Dosage: 0.5 mg/ear
Administration: topical; twice daily; 4 days
Result: Reduced chronic ear edema by 58%.
Decreased neutrophil infiltration by 65%, as measured by myeloperoxidase activity.
Showed no or only mild inflammation, dermal fibrosis, increased fibroblasts, an epithelium thickness of 5.9 cells, and 15.5 mastocytes per 1000 μm2 via histological analysis.
Animal Model: Swiss mice (female, 25-30 g)[1]
Dosage: 0.5 mg/ear
Administration: topical; doses at 6, 24, 48, 72, and 96 hours post-challenge
Result: Achieved 32% swelling inhibition at 24 hours post-challenge.
Showed no reduction in myeloperoxidase activity (no effect on neutrophil infiltration).
Molecular Weight

1073.26

Formula

C54H88O21
CAS No.
SMILES

C[C@]12[C@]3(C=C[C@@]4([H])[C@]2(CC[C@]5([H])[C@@]4(CC[C@@H]([C@@]5(C)CO)O[C@H]6[C@@H]([C@H]([C@H]([C@H](O6)C)O)O[C@@H]7O[C@@H]([C@H]([C@@H]([C@H]7O)O)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)CO)O[C@@H]9O[C@@H]([C@H]([C@@H]([C@H]9O)O)O)CO)C)C)[C@@]%10([H])[C@@](CC1)(CCC(C)(C%10)C)CO3
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Verbascosaponin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Verbascosaponin141896-30-2Ilwensisaponin A Mimengoside ADrug DerivativeDrug derivative12-O-tetradecanoylphorbol 13-acetateScrophularia auriculata L. ssp. pseudoauriculatacarrageenanoxazolonedelayed-type hypersensitivitymouse ear edemaarachidonic acidmouse paw edemaneutrophil infiltrationethyl phenylpropiolateInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Verbascosaponin
Cat. No.:
HY-N19870
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.